AGI Therapeutics plc is a publicly traded speciality pharmaceutical company focused on gastrointestinal drug products. AGI was established in 2003 by a group of highly experienced pharmaceutical industry executives who have a successful track record of developing, registering, partnering and bringing to market of pharmaceutical products in major global markets.
AGI is focused on the development and commercialisation of proprietary, innovative and differentiated therapeutic drug products for gastrointestinal (''GI'') diseases and disorders. Our products are based on re-profiling known drugs for GI clinical indications, either as a new GI use for a therapeutic drug already approved in a non-GI indication (a "therapeutic switch") or as a differentiated presentation in the already established GI clinical indication (an "improved therapy").
AGI has a portfolio of product candidates derived from the Known Molecular Entity (''KME'') approach to drug re-profiling and development. KME is a re-profiling methodology used by AGI to identify existing therapeutic drugs which typically have been marketed for a number of years, have established safety profiles and can be developed for new clinical indications or with improved profiles in their existing clinical indications. In this way, we seek to reduce the risk, time and cost of new product development as compared to the development of new chemical entities.
AGI is developing a range of product candidates to treat a variety of prevalent GI diseases and disorders, including irritable bowel syndrome, functional dyspepsia, ulcerative colitis and gastro-esophageal reflux disease. AGI is targeting areas of the GI therapeutic market for its product candidates where there are currently unmet medical needs or where the effectiveness of existing drug therapies can be further improved.
AGI currently has six clinical-stage product candidates which are either isomers or new drug delivery formulations of existing approved drugs, and which have established safety and tolerability profiles in their currently approved clinical indications. These product candidates are all in clinical development, five of which are in Phase II trials.
Our goal is to become a leading speciality pharmaceutical company focused on the treatment of gastrointestinal disorders. We plan to achieve this by:
-
aggressively developing our lead clinical candidates
-
reducing the risk, time and cost of product development through the KME approach
to drug re-profiling and development
-
providing improved therapeutic options for patients in large gastrointestinal markets
-
establishing alliances with leading pharmaceutical companies to enhance the global market reach for our products and achieve optimal revenue and value opportunities for the company
|
